222 related articles for article (PubMed ID: 11572942)
1. An expanded glutamine repeat destabilizes native ataxin-3 structure and mediates formation of parallel beta -fibrils.
Bevivino AE; Loll PJ
Proc Natl Acad Sci U S A; 2001 Oct; 98(21):11955-60. PubMed ID: 11572942
[TBL] [Abstract][Full Text] [Related]
2. Temperature-dependent, irreversible formation of amyloid fibrils by a soluble human ataxin-3 carrying a moderately expanded polyglutamine stretch (Q36).
Shehi E; Fusi P; Secundo F; Pozzuolo S; Bairati A; Tortora P
Biochemistry; 2003 Dec; 42(49):14626-32. PubMed ID: 14661975
[TBL] [Abstract][Full Text] [Related]
3. Recruitment and the role of nuclear localization in polyglutamine-mediated aggregation.
Perez MK; Paulson HL; Pendse SJ; Saionz SJ; Bonini NM; Pittman RN
J Cell Biol; 1998 Dec; 143(6):1457-70. PubMed ID: 9852144
[TBL] [Abstract][Full Text] [Related]
4. Caspase-mediated proteolysis of the polyglutamine disease protein ataxin-3.
Berke SJ; Schmied FA; Brunt ER; Ellerby LM; Paulson HL
J Neurochem; 2004 May; 89(4):908-18. PubMed ID: 15140190
[TBL] [Abstract][Full Text] [Related]
5. Progress in pathogenesis studies of spinocerebellar ataxia type 1.
Cummings CJ; Orr HT; Zoghbi HY
Philos Trans R Soc Lond B Biol Sci; 1999 Jun; 354(1386):1079-81. PubMed ID: 10434309
[TBL] [Abstract][Full Text] [Related]
6. Epigallocatechin-3-gallate and tetracycline differently affect ataxin-3 fibrillogenesis and reduce toxicity in spinocerebellar ataxia type 3 model.
Bonanomi M; Natalello A; Visentin C; Pastori V; Penco A; Cornelli G; Colombo G; Malabarba MG; Doglia SM; Relini A; Regonesi ME; Tortora P
Hum Mol Genet; 2014 Dec; 23(24):6542-52. PubMed ID: 25030034
[TBL] [Abstract][Full Text] [Related]
7. Characterization of the structure and the amyloidogenic properties of the Josephin domain of the polyglutamine-containing protein ataxin-3.
Masino L; Nicastro G; Menon RP; Dal Piaz F; Calder L; Pastore A
J Mol Biol; 2004 Dec; 344(4):1021-35. PubMed ID: 15544810
[TBL] [Abstract][Full Text] [Related]
8. Ataxin-3 with an altered conformation that exposes the polyglutamine domain is associated with the nuclear matrix.
Perez MK; Paulson HL; Pittman RN
Hum Mol Genet; 1999 Dec; 8(13):2377-85. PubMed ID: 10556285
[TBL] [Abstract][Full Text] [Related]
9. A major role for side-chain polyglutamine hydrogen bonding in irreversible ataxin-3 aggregation.
Natalello A; Frana AM; Relini A; Apicella A; Invernizzi G; Casari C; Gliozzi A; Doglia SM; Tortora P; Regonesi ME
PLoS One; 2011 Apr; 6(4):e18789. PubMed ID: 21533208
[TBL] [Abstract][Full Text] [Related]
10. Polyglutamine expansion in ataxin-3 does not affect protein stability: implications for misfolding and disease.
Chow MK; Ellisdon AM; Cabrita LD; Bottomley SP
J Biol Chem; 2004 Nov; 279(46):47643-51. PubMed ID: 15345714
[TBL] [Abstract][Full Text] [Related]
11. Destabilization of a non-pathological variant of ataxin-3 results in fibrillogenesis via a partially folded intermediate: a model for misfolding in polyglutamine disease.
Chow MK; Paulson HL; Bottomley SP
J Mol Biol; 2004 Jan; 335(1):333-41. PubMed ID: 14659761
[TBL] [Abstract][Full Text] [Related]
12. A genetic model for human polyglutamine-repeat disease in Drosophila melanogaster.
Bonini NM
Philos Trans R Soc Lond B Biol Sci; 1999 Jun; 354(1386):1057-60. PubMed ID: 10434305
[TBL] [Abstract][Full Text] [Related]
13. Amino acid sequences flanking polyglutamine stretches influence their potential for aggregate formation.
Nozaki K; Onodera O; Takano H; Tsuji S
Neuroreport; 2001 Oct; 12(15):3357-64. PubMed ID: 11711886
[TBL] [Abstract][Full Text] [Related]
14. The two-stage pathway of ataxin-3 fibrillogenesis involves a polyglutamine-independent step.
Ellisdon AM; Thomas B; Bottomley SP
J Biol Chem; 2006 Jun; 281(25):16888-16896. PubMed ID: 16624810
[TBL] [Abstract][Full Text] [Related]
15. Misfolding promotes the ubiquitination of polyglutamine-expanded ataxin-3, the defective gene product in SCA3/MJD.
Jana NR; Nukina N
Neurotox Res; 2004; 6(7-8):523-33. PubMed ID: 15639784
[TBL] [Abstract][Full Text] [Related]
16. Peptide models for inherited neurodegenerative disorders: conformation and aggregation properties of long polyglutamine peptides with and without interruptions.
Sharma D; Sharma S; Pasha S; Brahmachari SK
FEBS Lett; 1999 Jul; 456(1):181-5. PubMed ID: 10452554
[TBL] [Abstract][Full Text] [Related]
17. Mechanisms of ataxin-3 misfolding and fibril formation: kinetic analysis of a disease-associated polyglutamine protein.
Ellisdon AM; Pearce MC; Bottomley SP
J Mol Biol; 2007 Apr; 368(2):595-605. PubMed ID: 17362987
[TBL] [Abstract][Full Text] [Related]
18. Proteolytic cleavage of polyglutamine-expanded ataxin-3 is critical for aggregation and sequestration of non-expanded ataxin-3.
Haacke A; Broadley SA; Boteva R; Tzvetkov N; Hartl FU; Breuer P
Hum Mol Genet; 2006 Feb; 15(4):555-68. PubMed ID: 16407371
[TBL] [Abstract][Full Text] [Related]
19. Examination of Ataxin-3 (atx-3) Aggregation by Structural Mass Spectrometry Techniques: A Rationale for Expedited Aggregation upon Polyglutamine (polyQ) Expansion.
Scarff CA; Almeida B; Fraga J; Macedo-Ribeiro S; Radford SE; Ashcroft AE
Mol Cell Proteomics; 2015 May; 14(5):1241-53. PubMed ID: 25700012
[TBL] [Abstract][Full Text] [Related]
20. Destabilization of non-pathological variants of ataxin-3 by metal ions results in aggregation/fibrillogenesis.
Ricchelli F; Fusi P; Tortora P; Valtorta M; Riva M; Tognon G; Chieregato K; Bolognin S; Zatta P
Int J Biochem Cell Biol; 2007; 39(5):966-77. PubMed ID: 17300980
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
